文献速递儿童心血管与肾脏儿童呼吸儿童感染

每日低剂量泼尼松龙治疗上呼吸道感染预防儿童复发性激素敏感型肾病综合征复发:PREDNOS 2随机临床试验

Evaluation of Daily Low-Dose Prednisolone During Upper Respiratory Tract Infection to Prevent Relapse in Children With Relapsing Steroid-Sensitive Nephrotic Syndrome: The PREDNOS 2 Randomized Clinical Trial.
PubMed 文献 · JAMA Pediatr · 2022-01-01

PREDNOS 2为双盲安慰剂对照随机临床试验,纳入英国122个儿科部门的365例复发性激素敏感型肾病综合征患儿,评估上呼吸道感染时每日低剂量泼尼松龙6天能否预防复发。

要点

  • 上呼吸道感染时每日低剂量泼尼松龙6天未降低复发性激素敏感型肾病综合征患儿复发风险。
  • 未发现依据背景免疫抑制治疗的治疗效应差异,次要结局无显著差异。

核心结论

  • PREDNOS 2结果提示,在英国儿童中,上呼吸道感染时给予6天每日低剂量泼尼松龙不降低肾病综合征复发风险。

研究设计与样本

  • 双盲、安慰剂对照随机临床试验(PREDNOS 2),2013年2月1日至2020年1月31日在英国122个儿科部门评估365例复发性激素敏感型肾病综合征患儿,伴或不伴背景免疫抑制治疗。
  • 于上呼吸道感染开始时给予泼尼松龙15 mg/m2每日共6天或匹配安慰剂;已用隔日泼尼松龙者按试验药物调整至15 mg/m2每日或原隔日剂量中较大者。
  • 改良意向性分析人群271例,平均(SD)年龄7.6(3.5)岁,174例(64.2%)男性,泼尼松龙组134例、安慰剂组137例。

主要发现

  • 未发现依据背景免疫抑制治疗的治疗效应差异,次要结局两组间无显著差异。

关键数值与推荐

  • 干预:上呼吸道感染开始时泼尼松龙15 mg/m2每日共6天;已用隔日泼尼松龙者按试验药物调整至15 mg/m2每日或原隔日剂量中较大者。
  • 主要结局:首次上呼吸道感染相关复发发生率;次要结局包括总体复发率、背景免疫抑制治疗变化、泼尼松龙累积剂量、严重不良事件率、皮质类固醇不良反应发生率及生活质量。
  • 改良意向性分析人群271例(泼尼松龙组134例、安慰剂组137例);主要结局分析中两组各131例。

临床怎么用

  • 对于复发性激素敏感型肾病综合征患儿,上呼吸道感染时不应常规给予6天每日低剂量泼尼松龙以预防复发。
  • 临床决策应结合患儿背景免疫抑制治疗及族裔因素个体化评估,但本试验未发现依据背景免疫抑制治疗的治疗效应差异。
  • 需进一步研究不同族裔间治疗反应的差异。

局限性

  • 研究在英国进行,结论外推至其他地区人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In children with corticosteroid-sensitive nephrotic syndrome, many relapses are triggered by upper respiratory tract infections. Four small studies found that administration of daily low-dose prednisolone for 5 to 7 days at the time of an upper respiratory tract infection reduced the risk of relapse, but the generalizability of their findings is limited by location of the studies and selection of study population. OBJECTIVE: To investigate the use of daily low-dose prednisolone for the treatment of upper respiratory tract infection-related relapses. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, placebo-controlled randomized clinical trial (Prednisolone in Nephrotic Syndrome [PREDNOS] 2) evaluated 365 children with relapsing steroid-sensitive nephrotic syndrome with and without background immunosuppressive treatment at 122 pediatric departments in the UK from February 1, 2013, to January 31, 2020. Data from the modified intention-to-treat population were analyzed from July 1, 2020, to December 31, 2020. INTERVENTIONS: At the start of an upper respiratory tract infection, children received 6 days of prednisolone, 15 mg/m2 daily, or matching placebo preparation. Those already taking alternate-day prednisolone rounded their daily dose using trial medication to the equivalent of 15 mg/m2 daily or their alternate-day dose, whichever was greater. MAIN OUTCOMES AND MEASURES: The primary outcome was the incidence of first upper respiratory tract infection-related relapse. Secondary outcomes included overall rate of relapse, changes in background immunosuppressive treatment, cumulative dose of prednisolone, rates of serious adverse events, incidence of corticosteroid adverse effects, and quality of life. RESULTS: The modified intention-to-treat analysis population comprised 271 children (mean [SD] age, 7.6 [3.5] years; 174 [64.2%] male), with 134 in the prednisolone arm and 137 in the placebo arm. The number of patients experiencing an upper respiratory tract infection-related relapse was 56 of 131 (42.7%) in the prednisolone arm and 58 of 131 (44.3%) in the placebo arm (adjusted risk difference, -0.02; 95% CI, -0.14 to 0.10; P = .70). No evidence was found that the treatment effect differed according to background immunosuppressive treatment. No significant differences were found in secondary outcomes between the treatment arms. A post hoc subgroup analysis assessing the primary outcome in 54 children of South Asian ethnicity (risk ratio, 0.66; 95% CI, 0.40-1.10) vs 208 children of other ethnicity (risk ratio, 1.11; 95% CI, 0.81-1.54) found no difference in efficacy of intervention in those of South Asian ethnicity (test for interaction P = .09). CONCLUSIONS AND RELEVANCE: The results of PREDNOS 2 suggest that administering 6 days of daily low-dose prednisolone at the time of an upper respiratory tract infection does not reduce the risk of relapse of nephrotic syndrome in children in the UK. Further work is needed to investigate interethnic differences in treatment response. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN10900733; EudraCT 2012-003476-39.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Christian MT, Webb NJA, Mehta S, et al. Evaluation of Daily Low-Dose Prednisolone During Upper Respiratory Tract Infection to Prevent Relapse in Children With Relapsing Steroid-Sensitive Nephrotic Syndrome: The PREDNOS 2 Randomized Clinical Trial. JAMA Pediatr. 2022. PMID: 34928294. doi:10.1001/jamapediatrics.2021.5189

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。